Tanzania's antiretroviral distribution program expands after slow start

Tanzania's antiretroviral drug distribution program began slowly but is accelerating, with the number of people receiving treatment doubling over the past 10 months, IRIN News/AllAfrica.com reports.

By mid-September, 49,315 people were receiving antiretrovirals from state facilities, compared with 23,000 people in December 2005, according to the National AIDS Control Programme.

Emma Msuya Lekashingo, NACP's head of care and treatment, said the increase is because of increased funding and a facilitated procurement process, which previously often took many months and sometimes years to complete.

Despite the increase, the latest treatment figures fall far short of NACP's goals of treating 66,000 HIV-positive people by the end of 2005 and having 104,000 people receiving antiretrovirals by the end of 2006.

According to the World Health Organization, 315,000 people in Tanzania need antiretroviral treatment. Fifteen percent of these people are covered by the program, IRIN News/AllAfrica.com reports.

Treatment distribution is being slowed by the inaccessibility of many areas, deep-rooted cultural misconceptions about HIV/AIDS and stigma, according to Lekashingo.

The government has set aside $22 million in the 2006-2007 budget for NACP, IRIN News/AllAfrica.com reports.

According to NACP, the new government funding will be used to buy antiretrovirals and condoms to be distributed at no cost in many government hospitals and health centers across the country to improve access to treatment and prevention for people in rural areas (IRIN News/AllAfrica.com, 10/25).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Affordability and supply remain critical to the success of long-lasting HIV drug